好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Exploratory Efficacy of INP104 in Migraine Patients By Prior Treatment
Headache
P13 - Poster Session 13 (8:00 AM-9:00 AM)
15-001

To report data from a post hoc analysis of the exploratory efficacy of INP104 treatment over 24 weeks based on acute medications used prior to INP104 treatment.

Data suggests that patients are not satisfied with their current acute therapies for migraine. INP104 is a drug-device combination product for the acute treatment of migraine that targets delivery of dihydroergotamine mesylate to the upper nasal space using Precision Olfactory Delivery (POD®) technology. Previously presented data showed that INP104 was well tolerated and associated with improvements in several exploratory efficacy outcomes.
STOP 301 was a pivotal, Phase 3, open-label study that assessed the safety, tolerability, and exploratory efficacy of INP104. Patients were on their best usual care during a 28-day screening period (i.e. baseline). Eligible patients continued into a 24-week treatment period and were provided with INP104 to nasally self-administer (1.45 mg) with self-recognized migraine attacks. Daily eDiaries were completed to capture headache and migraine details. 
A total of 354 patients self-administered ≥1 dose of INP104 over 24 weeks and were included in this analysis. The most commonly used acute therapies prior to INP104 treatment initiation were acetaminophen (43.8%), nonsteroidal anti-inflammatory drugs (NSAIDs; 37.6%), and triptans (28.2%). During Weeks 1-12, migraine attacks self-reported as pain- and most bothersome symptom (MBS)-free at 2 hours post-INP104 were 37% and 54% (n=1152) in acetaminophen users, 36% and 53% (n=1048) in NSAID users, and 39% and 55% (n=732) in triptan users. During Weeks 13-24, corresponding pain- and MBS-free rates at 2 hours post-INP104 were 37% and 50% (n=843) in acetaminophen users, 34% and 53% (n=691) in NSAID users, and 42% and 59% (n=449) in triptan users. 
Results suggest that INP104 may be an effective acute treatment option for migraine patients regardless of their prior acute treatment, which includes triptans. 
Authors/Disclosures
Tanya Bilchik, MD (Yale University Department of Neurology)
PRESENTER 		Dr. Bilchik has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie.
Robert Vann, PhD (C2N Diagnostics) Dr. Vann has received personal compensation for serving as an employee of Impel Neuropharma. Dr. Vann has received personal compensation for serving as an employee of Biogen.
Sutapa Ray, PhD (Impel NeuroPharma) Dr. Ray has received personal compensation for serving as an employee of Impel Pharmaceuticals. Dr. Ray has stock in Impel Pharmaceuticals.
Stephen B. Shrewsbury, MD (Impel Pharmaceuticals) Dr. Shrewsbury has received personal compensation for serving as an employee of Impel NeuroPharma. Dr. Shrewsbury has received stock or an ownership interest from Impel NeuroPharma.
Sheena K. Aurora, MD (Department of Neurology and Neurological Sciences) Dr. Aurora has received personal compensation for serving as an employee of Alzheimer's Association.